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(57) ABSTRACT 
Here we disclose the response of normal human cells to ZnO 
nanoparticles under different signaling environments and 
compare it to the response of cancerous cells. ZnO nanopar-
ticles exhibit a strong preferential ability to kill cancerous T 
cells (-28-35X) compared to normal cells. Interestingly, the 
activation state of the cell contributes toward nanoparticle 
toxicity as resting T cells display a relative resistance while 
cells stimulated through the T cell receptor and CD28 
costimulatory pathway show greater toxicity in direct relation 
to the level of activation. The novel findings of cell selective 
toxicity towards potential disease causing cells indicate a 
potential utility of ZnO nanoparticle in the treatment of can-
cer and/or autoimmunity. 
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PREFERENTIAL KILLING OF CANCER 
CELLS AND ACTIVATED HUMAN T CELLS 
USING ZNO NANOPARTICLES 
This application claims priority of Provisional Application 5 
Ser. No. 601974,460, filed Sep. 22, 2007, and entitled "Pref-
erential Killing of Cancer Cells and Activated Human T Cells 
Using the Selective Toxicity of Zinc Oxide," which is hereby 
incorporated by reference. 
This research was supported in part by Mountain States 10 
Tumor and Medical Research Institute, Boise, Id., NSF-
Idaho-EPSCoR Program (EPS-0447689), DoE-EPSCoR 
grant (DE-FG02-04ER46142), NSF grants (DMR-0449639, 
MRI 0521315), and NIH (lR15 AI06277-0IAI). We thank 
Dr. lames Belthofffor his gracious assistance with statistical 15 
analysis. 
BACKGROUND OF THE INVENTION 
2 
213903). The aim of the study was to investigate whether ZnO 
NP induce toxicity in a cell-specific manner, determine the 
mechanism( s) of toxicity, and whether these NPs have poten-
tial utility in novel biomedical applications seeking to elimi-
nate pathogenic cells while sparing healthy body tissues. 
SUMMARY OF INVENTION 
Nanoparticles are increasingly being recognized for their 
potential utility in biological applications including nano-
medicine. Here we examine the response of normal human 
cells to ZnO nanoparticles under different signaling environ-
ments and compare it to the response of cancerous cells. ZnO 
nanoparticles exhibit a strong preferential ability to kill can-
cerous T cells (-28-35X) compared to normal cells. Interest-
ingly, the activation state of the cell contributes toward nano-
particle toxicity as resting T cells display a relative resistance 
while cells stimulated through the T cell receptor and CD28 
costimulatory pathway show greater toxicity in direct relation 
1. Field of the Invention 
This invention relates generally to a new method for pref-
erentially killing cancer and activated T cells with zinc oxide 
(ZnO) nanoparticles. More specifically, this invention relates 
to autoimmune disease and cancer treatment in humans and 
animals by preferentially killing cancer and activated T cells 
with relatively little damage to normal cells. 
20 to the level of activation. Mechanisms of toxicity appear to 
involve the generation of reactive oxygen species (ROS) with 
cancerous T cells producing higher inducible levels than nor-
mal T cells. In addition, nanoparticles were found to induce 
apoptosis and the inhibition of ROS was found to be protec-
2. Background Art 
25 tive against nanoparticle induced cell death. The novel find-
ings of cell selective toxicity towards potential disease caus-
ing cells indicate a potential utility of ZnO nanoparticle in the 
treatment of cancer and/or autoimmunity. The integration of nanotecluology and biology provides 
the opportunity for the development of new materials in the 
nanometer size range that may be applied to many potential 30 
applications in biological science and clinical medicine. 
When reduced to the nanoscale realm, unique size-dependent 
properties of nanomaterials, including nanopaiticles (NP), 
are manifested. The principal factors believed to cause prop-
erties of nanomaterials to differ from their bulk counterparts 35 
include an increase in relative surface area and quantum 
effects, which can affect chemical reactivity and other physi-
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is two charts about ZnO NP toxicity on unactivated 
verses activated primary human CD4+ T cells. 
FIG. 2 is three charts about the activation of T cells pro-
moting NP association. 
FIG. 3 is two charts about differential cytotoxic effects of 
ZnO NP on cancerous T cell lines and primary T cells. 
FIG. 4 is a chart about viability effects of ZnO NP on 
co-cultures of cancerous and normal T cells. 
FIG. 5 is a chart about kinetics of ZnO NP toxicity on 
immortalized and primary human T cells. 
FIG. 6 is three charts about cellular production of ROS 
following ZnO NP exposure. 
cal and chemical properties. For example, a particle oBO um 
size has 5% of it atoms on its surface compared to 50% of the 
atoms on the surface of a 3 nm particle. The altered properties 40 
of NP, and their similarity in size compared to naturally 
occurring biological structures, can allow them to readily 
interact with biomolecules on both the cell surface and within 
the cell and potentially affect cellular responses in a dynamic 
and selective manner. Materials that exploit these character-
istics are becoming increasingly attractive for use in novel 
biomedical applications. 
FIG. 7 is a chart about quenching ofROS protecting against 
45 NP-mediated cytotoxicity. 
FIG. 8 is seven copies of photos about ZnO NP inducing 
apoptosis in lurkat T cells. 
FIG. 9 is three copies of photos about detection of apop-
totic morphological changes in lurkat T cells treated with 
50 ZnONP. 
Although our understanding of the functioning of the 
human body at the molecular and nanometer scale has 
improved tremendously, advances in therapeutic options for 
treating severe and debilitating diseases such as cancer and 
autoimmunity have lagged by comparison. In this regard, 
nanomedicine, which is the application of nanotechnology to 
medical problems, can offer new approaches. With regards to 
cancer treatment, most current anticancer regimes do not 
effectively differentiate between cancerous and normal cells. 
This indiscriminate action frequently leads to systemic tox-
icity and debilitating adverse effects in normal body tissues 
including bone marrow suppression, neurotoxicity, and car-
diomyopathy. Nanotechnology and nanomedicine can offer a 60 
more targeted approach which promises significant improve-
ments in the treatment of cancer. In this study we have 
employed 8 nm zinc oxide (ZnO) NP in which the synthesis 
and properties have been previously described (Reddy K M, 
Feris K, Bell l, Wingett D G, Hanley C, Punnoose A 2007 65 
Selective toxicity of zinc oxide nanoparticles to prokaryotic 
and eukalyotic systems Applied Physics Letters 90 213902-
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
55 Materials and Methods 
I. Preparation and Characterization of Zinc Oxide Nanopar-
ticles 
ZnO nanoparticles were synthesized in diethylene glycol 
(DEG) by forced hydrolysis of zinc acetate at 1600 C. as 
previously described and size control achieved by optimizing 
the hydrolysis ratio. The ZnO NPs were separated from DEG 
via centrifugation (15,000 rpm), washed with ethanol several 
times and dried to obtain a nanoscale powder sample. The 
ZnO chemical phase, crystallite size (8-13 nm) and shape 
were confirmed using x-ray diffraction (XRD), transmission 
electron microscopy (TEM) and spectrophotometry. The 
nanoparticles were then reconstituted in phosphate buffered 
US 8,187,638 B2 
3 
saline (PBS) solution. After reconstitution, NPs were soni-
cated for 10 min and immediately vortexed before addition to 
cell cultures. 
In order to aid in the investigations, additional FITC encap-
sulated ZnO (FITC-ZnO) particles were synthesized by 5 
forced hydrolysis and condensation of FITC-binding silane 
and silicate to obtain the FITC-Si02 core (Burns A, Ow H, 
and Wiesner U 2006 Fluorescent core-shell silica nanopar-
ticles: towards "Lab on a Particle" architectures for nanobio-
technology. Chern. Soc Rev. 35 1028-1042) and then the ZnO 10 
surface layer fonned using zinc salt as described previously 
Wang H, Wingett D, Engelhard M H, Feris K, Reddy K M, 
Turner P et al 2008 Fluorescent dye encapsulated ZnO par-
ticles with cell-specific toxicity for cancer treatment and bio-
medical applications submitted to J Material Science: Mate- 15 
rials in Medicine. The core-shell structure of the -200 nm 
sized FITC-ZnO particles and the presence of a surface layer 
of 8-13 nm sized ZnO nanopaiticles were confinned using 
TEM, XRD and x-ray photoelectron spectroscopy (XPS) 
studies, and fluorescence properties were investigated using 20 
photolnminescence spectroscopy and flow cytometry, as 
reported previously. 
2. Isolation ofCD4+ T Lymphocytes and Cell Culture 
Written, informed consent was obtained from all blood 
donors and the University Institutional Review Board 25 
approved the study. Peripheral blood mononuclear cells 
(PBMC) were obtained by Ficoll-Hypaque (Histopaque-
1077, Sigma, St. Louis, Mo.) gradient centrifugation using 
heparinized phlebotomy samples. Cells were washed 3 times 
with Hank's buffer (Sigma) and incubated at Ixl06 cells/mL 30 
in RPMI-1640 (Sigma) containing 10% fetal bovine serum 
(FBS). CD4+ cells were obtained by negative immunonmag-
netic selection per manufacturer's instructions using a cock-
tail of antibodies against CD45RO, CD8, CDI9, CDI4, 
CDI6, CD56, CD8, and glycophorinA (StemCell Technolo- 35 
gies, Vancouver, B.C.) with collection of unlabeled T cells 
(typically >96% CD4+ and >90% viable as assessed by flow 
cytometry). Purified CD4+ cells were cultured in RPMI/lO% 
FBS at Ix106 cells/ml in 200 flL total volume in 96-well 
microtiter plates. The lurkat and Hut-78 T cell lines (ATTC, 40 
Rockville, Md.) were cultured in RPMI 1640 supplemented 
with 10% FBS (Jurkat) or 20% FBS (Hut-78) and 2 mM 
L-glutamine, 1.5 giL sodinm bicarbonate, 4.5 giL glucose, 10 
mM HEPES, and 1.0 mM sodinm pyruvate. Cells were main-
tained in log phase at 37° C. and 5% CO2 and seeded at Ix105 45 
cells/well in 96-well plates for individual experiments. To 
prevent overgrowth in co-culture experiments, lurkat cells 
were seeded at 5x104 cells/well and primary T cells were 
seeded at Ix105 cells into the same well. 
4 
gated on size (forward scatter-FS) and granularity (side scat-
ter-SSC) were analyzed, and expression of the percentage of 
positively staining cells or the mean fluorescence intensity 
(MFI) was determined by comparisons to isotype controls. 
Appropriate concentrations of each antibody were deter-
mined by titration for optimal staining prior to experimental 
use. 
To assess cell viability, two different assays were 
employed. In the first assay, T cells were dually stained with 
fluoroscein isothiocyanate labeled antibodies (anti -CD4 for 
primary T cells and anti-HLA ABC for T cancer cell lines) 
followed by treatment with 50 flg/mL propidinm iodide (PI) 
to monitor losses in membrane integrity. After 10 min of PI 
staining, fluorescent CountBright counting beads (Invitro-
gen, Carlsbad, Calif.) were added to samples to enable deter-
minations of absolute cell nnmbers, and changes in PI stain-
ing used to quantifY cell death. Nanoparticles were excluded 
from analysis based on absence of fluorescence signal and 
light forward scatter (FS) and side scatter (SSC) characteris-
tics. A second viability assay, the LIVEIDEAD viability 
assay for mammalian cells (Invitrogen, Eugene, Oreg.) was 
used to verifY results. Per manufacturer's protocol for flow 
cytometry, cells were dually stained with two fluorescently 
labeled probes that enable the simultaneous detennination of 
live and dead cells in a sample. CalceinAM was used to stain 
live cells as it fluoresces only when cleaved by intracellular 
esterases and EthD-I was used to identifY dead! dying cells as 
it exclusively enters cells with disrupted cell membranes. 
In co-culture experiments, lurkat cells and primary T cells 
were distinguished from each other using differential gating 
based on their differing and non-overlapping light scattering 
properties indicative of size (FS) and granularity (SSC) 
between the two cell types. FS and SSC of lurkat cells was 
-2.2 and 3.2 times greater than for primary T cells, respec-
tively. 
5. ROS Production 
To assay for reactive oxygen species (ROS) production, 
primary hnman T cells were treated with the oxidation-sen-
sitive dye, 2', 7'-dichlorofluorescein diacetate (DCFH-DA; 
Invitrogen, Carlsbad, Calif.). The oxidation product of 
DCFH-DA has an excitation/emission maxima of -495 
nml529 nm enabling detection using standard flow cytom-
etry. Whole blood was treated with an ammonium chloride 
solution (1.5 M NH4 CI, 0.1 M NaHC03 , 0.01 M EDTA) to 
lyse red blood cells and centrifuged for 10 min at 4°C. to 
remove erythrocytic debris. The white blood cells were then 
resuspended in phenol red-free RPMI a Ix106 cells/mL and 
treated with 13 nm ZnO NP.After 18 h of treatment, cultures 
3. T-Cell Activation 
For indicated experiments, primary human T cells were 
activated using immobilized CD3 antibody (1.0 flglwell of 
clone OKT3, ATCC, Rockville, Md.) +/-CD28 antibody 
(0.25 flglwell of clone CD28.2, PharMingen, San Diego, 
Calif.) in 96-well tissue culture plates. Cultures were treated 
with freshly prepared and sonicated NP for varying lengths of 
time and flow cytometry used to assess T cell viability via 
staining with propidium iodide (PI: BD Biosciences). T cell 
activation was verified by detecting an increase in membrane 
CD40L protein expression using flow cytometry. 
50 were loaded with 5 flM of DCFH-DA for 20 min and ROS 
production evaluated using flow cytometry as previously 
described. To ensure cells were capable of ROS production, 
control samples were activated with 25 nglmL ofPMA for I 
h after loading with DCFH -DA. White blood cell populations 
4. Cell Viability and Flow Cylometry Staining 
Methods of immunofluorescent staining and flow cytom-
etry were perfonned as previously described. Briefly, cells 
were stained with fluorescently labeled antibodies (Beckman 
Coulter, Miami, Fla.) for 30 minutes at 4° c., washed two 
times, and immediately analyzed on a 3-color Epics flow 
cytometer (Beckman Coulter). Five to ten thousand events 
55 (i.e. T lymphocytes andmonocytes) were distinguished by FS 
and SSC characteristics and staining with fluorescently-Ia-
beled antibodies (e.g. CD3, CD 14). ROS production was also 
perfonned in Hut-78 cells using similar methodology. 
60 
6. ROS Quenching 
To detennine the role of ROS in NP-induced cell death, 
lurkat leukemia cells were seeded in a 96-well plate at 0.2 mL 
per well at a concentration of 5xl 05 cells/mL. A stock solu-
tion ofN-Acetyl Cysteine (NAC, Sigma Aldrich) was made in 
sterile nanopure water and added to cells at 5 mM or 10 mM 
65 for I h. After NAC pretreatment, cells were cultured with 
0.3-0.5 mM ZnO NP for 24 h. Viability was determined by PI 
exclusion and flow cytometry with fluorescent CountBright 
US 8,187,638 B2 
5 
counting beads (Invitrogen, Carlsbad, Calif.) added to 
samples to enable detennination of absolute cell numbers. 
7. Detection of Apoplosis 
6 
22-24 h and cell viability determined using flow cytometry 
and PI uptake (means±standard error, n=6). Statistical analy-
sis was performed using repeated measures analysis of vari-
ance and model based means post hoc test (p<0.05) with an 
asterisk denoting statistical significance. B) Verification ofT 
cell activation was detennined by concurrently monitoring 
expression of membrane CD40L protein using flow cytom-
etry (means±standard error, n=5). As shown in FIG. lA, the 
toxicity of ZnO NP to T cells is dependent on the activation 
Mechanisms of ZnO NP induced cytotoxicity was evalu-
ated by confocal microscopy using two different staining 5 
techniques; acridine orange and Vybrant® Apoptosis Assay 
Kit #2-AlexaFluor® annexin V/propidium iodide by Invit-
rogen (Eugene, Oreg.). Acridine orange stains double 
stranded DNA and allows for visualization of nuclear mor-
phology. Invitrogen's Vybrant annexin V assay makes use of 
two different fluorescently labeled probes, annexin V and PI, 
10 state of the cell. Resting T cells displayed the most resistance 
to ZnO NP, with an ICso of -5.9 mM. The inactivated status of 
these cells was verified by their lack of appreciable CD40L 
protein expression, a sensitive marker of T cell activation 
(FIG. IB). Conversely, T cells partially activated by stimula-
to differentiate between live, necrotic and apoptotic cells. 
Briefly, lurkat T cells were suspended in complete RPMI-
1640 medium and plated at 5x1Os on poly-d lysine coated 
glass bottom culture dishes (P35GC-1.5 mm-14 mm-C) sup-
plied by MatTek Corporation (Ashland, Mass.). Samples 
were left untreated, treated with 0.3 mM ZnO NP, or with 100 
nM okadaic acid as a positive control for apoptosis. Follow-
ing a 20 h incubation at 37° C. (5% CO2 ), cells were washed 
and stained with annexin V antibody/PI per manufacturer's 
protocol or stained with 5 flglmL acridine orange for 10 min 
15 tion thorough the TCR pathway alone displayed significantly 
greater sensitivity to ZnO NP at all concentrations tested 
(p=0.0007 for control vs. CD3 at 1 mM, p=0.0009 at 5 mM 
and p=0.0052 at 10 mM NP). The partial activation status of 
these cells was verified by 38%±6.2% of the cells expressing 
20 membrane CD40L. Importantly, T cells activated through 
both the TCR and CD28 costimulatory pathway showed an 
even greater sensitivity to ZnO NP toxicity (e.g. 55% viability 
in CD3/CD28 activated vs. 69% in CD3 activated cells at 1 
at 37° c., followed by washing and resuspension in PBS. 
Cells were visualized using a Zeiss LSM 510 META laser 
scanning confocal microscope (Zeiss, Gennany). Images 
were acquired using factory-set dichronics (an argon laser set 25 
and two helium neon lasers) with either a 63x Plan Apochro-
mat 1.4 oil DIC or 100x Plan Fluar 14.5 oil objective. Image 
acquisition and processing was performed using the LSM 510 
META software. 
mM) which significantly differed from CD3 activated cul-
tures at both 1 mM (p=0.0044) and 5 mM NP (p=0.0246) 
concentrations. Staining for membrane CD40L expression 
was used to confinn a greater extent of T cell activation in 
CD3/CD28 activated cultures (67%± 7.0% cells staining posi-
tive for membrane CD40L). Control experiments using bulk 
8. Statistical Analyses 
All data was analyzed using SAS, Inc. software (Cary, 
N.C.). Data for FIGS. 1, 3A, and 4 were analyzed using 
repeated measures of valiance with post hoc comparisons and 
significance levels defined as p<0.05. Repeated measures of 
variance analyses were used when two or more measurements 
of the same type were made on the same subject to detennine 
statistical differences between the means and allow within-
subject variation to be separated from between-subject varia-
tion. Data for FIGS. 3B and 7 were analyzed using a two-way 
analysis of variance (ANOVA) to test for statistical signifi-
cance of the model and post hoc comparisons were used to 
test for statistically significant effects of treatment on cell 
viability (p<0.05). 
30 micron sized ZnO powder or NP-free supernatant showed no 
appreciable toxicity effect at any of the concentrations tested 
(viability with bulk ZnO: 95±0.5% at 0 mM, 96±3% at 1 mM, 
91±3% at 5 mM, 91±1 % at 10 mM; 98% viability with 
NP-free supernatant equivalent to 1-10 mM) consistent with 
35 our previous observations. 
In addition to PI uptake associated with disruption of mem-
brane integrity, cell death following ZnO NP treatment was 
also supported by an increase (-17%; MFI change of 48 to 56) 
in light side scatter characteristics which is indicative of 
40 increased cellular granularity and a concurrent decrease 
(-8%; MFI change of 156 to 144) in forward scatter which 
reflects a decrease in cellular size at 10 mM NP concentra-
tions that induce -60% cell death. These results demonstrate 
Results that significantly more cell death is observed in activated T 
1. Activated T Cells are Preferentially Killed by ZnO NP 45 cells compared to resting cells over a relatively large range of 
NP concentrations tested (1-10 mM), and toxicity varies with 
the extent ofT cell activation. 
Previous studies from our laboratory have determined that 
toxicity of ZnO NP occurs in a cell dependent manner. For 
example, both gram negative and grain positive bacteria are 
killed at substantially lower ZnO NP concentrations than 
human T cells. To detennine if differential toxicity to ZnO NP 50 
is dependent upon the microenvironment or signaling status 
of cell, toxicity effects were determined in resting primary 
human T cells and compared to cells activated through the T 
cell receptor (TCR). Nonnal peripheral blood CD4+ T cells 
were isolated using negative immunomagnetic selection and 55 
either activated with stimulatory TCR antibodies (anti-CD3), 
costimulated with anti-CD3/anti-CD28, or left unactivated. 
The effects of ZnO NP on plasma membrane damage was 
assessed using propidium iodide (PI), a red fluorescent 
nuclear stain that enters only cells with disrupted plasma 60 
membranes. 
According to FIG. 1, ZnO NP toxicity on unactivated ver-
sus activated primary human CD4+ T cells. A) Human periph-
eral blood CD4+ T cells were isolated (purity >95%) and 
activated with anti-CD3 antibodies, a combination of anti- 65 
CD3 and anti-CD28, or left unactivated. Cultures were con-
currently treated with varying concentrations of ZnO NP for 
2. ZnO NP Preferentially Associate with Activated T Cells 
To gain insights into mechanisms of differential cell tox-
icity, experiments were perfonned to determine whether NP 
preferentially associate with activated T cells compared to 
resting T cells. FITC-encapsulated ZnO NP (FITC-ZnO-NP) 
were prepared as described and their fluorescence properties 
used to monitor cell uptake/association. Primary CD4+ T 
cells were either left unactivated or activated with CD3/CD28 
antibodies and treated with 5 mM FITC-ZnO-NP for 4 h. 
Dual color flow cytometry was used to analyze changes in the 
FITC-NP signal on gated CD4+ T cells. 
According to FIG. 2, the activation ofT cells promotes NP 
association. Primary CD4+ T cells (>96% purity) were left 
untreated or activated with immobilized CD3/CD28 antibod-
ies and cultures concurrently treated with 5 mM FITC encap-
sulated ZnO NP for 4 h. Cells were stained using an ECD-
labeled CD4 Ab. Using flow cytometry, 10,000 events gated 
on CD4+ cells were analyzed for changes in FITC fluores-
cence. Data from a representative histogram is presented with 
panel A) showing resting T cells cultured with FITC encap-
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sulated NP and panel B) showing activated T cells cultured 
with FITC encapsulated NP. Inset numbers depict the per-
centage ofFITC positive cells. The positioning of the quad-
rant on the x-axis was determined using T cells cultured 
without fluorescently labeled NP and set so I % of cells 5 
appeared in quadrant 2. C) depicts a dose-dependent increase 
in NP association with T cells, n=3 with error bars depicting 
standard error. As shown in FIG. 2, resting T cells had a low 
NP associated fluorescence signal (12.5% FITC positive) 
while a substantially greater FITC signal (48.4% positive) 10 
was observed for activated T cells. A dose-dependent uptake 
ofFITC-ZnO-NP was noted with greater NP association at 5 
mM compared to I mM concentrations (-3.3 greater attach-
ment at 5 mM; FIG. 2C). At the early time points evaluated in 
these studies, NP labeling did not appear to reflect a general- 15 
ized increase in membrane permeability as no PI uptake 
indicative of cytotoxicity was observed following 4 h of expo-
sure with 5 mM FITC-ZnO-NP. However, the expected loss of 
cell viability (73%±7.3% sue., n=3 with 1.25 mM) was 
detected upon extended 24 h exposure indicating that FITC- 20 
ZnO-NP behave similarly to unlabeled ZnO NP. In addition, 
our recent confocal microscopic studies have demonstrated 
FITC-ZnO-NP uptake and intracellular localization by 
human T cells. Collectively, these results indicate that the 
cellular processes accompanying T cell activation (eg. 25 
increased membrane protein expression, cell cycle progres-
sion) result in changes that promote strong physical interac-
tions and consequent intracellular uptake of NP. 
3. Preferential Killing of Cancerous Cells by ZnO NP 
Given that differential ZnO NP toxicity exists between 30 
quiescent T cells and those activated with specific signals to 
trigger proliferation (FIG. 1), experiments were performed to 
determine whether continuously dividing cancer cells display 
an even greater sensitivity to ZnO NP toxicity. lurkat leuke-
mic and Hut-78 lymphoma T cell lines were treated with ZnO 35 
NP for 24 h and viability was determined by PI uptake. Both 
T cell cancer lines displayed strikingly greater (28-35 fold) 
sensitivity to NP toxicity compared to resting normal T cells 
(FIG. 3). 
According to FIG. 3, differential cytotoxic effects of ZnO 40 
NP on cancerous T cell lines and primary T cells. A) lurkat, 
Hut-78 T cell lines, or normal primary T cells were treated 
with varying concentrations ofZnO nanopaiticles for 22-24 h 
and viability determined by monitoring PI uptake using flow 
cytometry as described for FIG. 1. Data from seven (lurkat), 45 
three (Hut-78), and four (normal CD4+ T cells) independent 
experiments is presented and error bars depict standard error. 
Data was analyzed using a repeated measures ANOVA and 
model based means post test. Statistical comparisons were 
made between each cancer cell line and primary T cells at 0.1 50 
mM and 0.5 mM ZnO NP with significance levels defined as 
p<0.05 and indicated by an asterisk. B) lurkat and primary T 
cell viability was assessed using the LIVEIDEAD®Viability/ 
Cytotoxicity Kit for mammalian cells (Invitrogen, Eugene, 
Oreg.). Following ZnO NP exposure for 24 h, cells were 55 
stained with calcein AM (green fluorescence) and ethidium 
homodimer-I (red fluorescence) to differentiate between live 
and dead cells, respectively. Data from a representative 
experiment is presented with error bars depicting standard 
error, n=3. A two-way analysis of variance combined with a 60 
model based means test indicates significant differences in 
viability between lurkat and primary T cells for all NP con-
centrations tested (asterisk denotes p<O.OOOI). Significant 
differences were observed between Hut-78 and normal T 
cells (p=0.010l and 0.0434 at I mM and 5 mM NP, respec- 65 
tively) and lurkat and normal T cells «0.0001 at both I mM 
and 5 mM NP). An ICso of -0.17 mM was observed for 
8 
Hut-78 cells and -0.21 mM for lurkat T cells. No appreciable 
loss of primary T cell viability was observed at NP concen-
trations (e.g. 0.5 mM) that effectively killed the cancerous T 
cells. 
To validate experimental results, a second viability assay 
was employed. Similar experiments were performed using 
the LIVE/DEAD viability assay (Invitrogen, Eugene, Oreg.) 
which allows for the simultaneous determination of live and 
dead cells in a sample by labeling live cells with the Calcein 
AM dye that fluoresces only when cleaved by intracellular 
esterase enzymes and the vital dye, EthD-I, which only enters 
dead/dying cells with disrupted cell membranes. As shown in 
FIG. 3B, nearly identical results were obtained using this 
independent assay for viability, with ZnO NP displaying pref-
erential toxicity against cancerous cells compared to normal 
cells of identical lineage. It should be noted that no statisti-
cally significant change in primary T cell viability occurs 
between untreated control cells and cells treated with low NP 
concentrations (0.2 and 0.5 mM), while a significant decrease 
(p<0.000l) in lurkat leukemia cell viability can readily be 
seen at the lowest concentration tested (-52% viable/48% 
dead at 0.2 mM) with no live cancer cells detectable at 5 mM 
NP. 
To verifY that preferential cancer cell killing occurs in the 
direct presence of normal healthy T cells, co-culture experi-
ments were performed. For these experiments, lurkat T cells 
were co-cultured with primary CD4+ T cells, treated with 
various concentrations of ZnO NP for 24 h, and cell viability 
assessed by PI uptake. 
According to FIG. 4, viability effects of ZnO NP on co-
cultures of cancerous and normal T cells. Individual wells in 
a 96-well plate were seeded with lurkat and primary T cells 
and treated with various concentrations of ZnO nanopaiticles 
for 22-24 h. Viability was determined by monitoring PI 
uptake using flow cytometry. Data from three independent 
experiments is presented and error bars depict standard error. 
Statistical analysis was performed using a repeated measures 
ANOVA and model based means post hoc test. Significance 
levels were defined as p<0.05 and are indicated by an asterisk. 
FIG. 4 confirms the preferentially killing of cancerous lurkat 
T cells with a very similar ICso value being observed for 
co-cultured lurkat cells (ICso -0.28 mM) compared to these 
cells cultured alone (FIG. 3). Again, only very limited cyto-
toxicity was observed on co-cultured normal T cells at corre-
sponding NP concentrations with significant differences 
(p<0.000l) between cell types being observed at 0.3,0.4, and 
0.5 mM NP concentrations. 
4. Kinetics of ZnO NP Mediated Toxicity 
Additional experiments were performed to determine the 
kinetics of ZnO NP toxicity in both primary and cancerous T 
cells. Because primary and immortalized T cells have mark-
edly different sensitivities to ZnO NP, concentrations were 
chosen for each cell type (10 mM for primary T cells and 0.5 
mM for lurkat T cells) that produce at least 75% cytotoxicity 
by 24 h exposure. 
According to FIG. 5, kinetics of ZnO NP toxicity on 
immortalized and primary human T cells. Freshly isolated 
CD4+ T cells (purity >96%) were treated with 10 mM ZnO 
NP and lurkat T cells were treated with 0.5 mM ZnO NP for 
varying times and viability determined using PI uptake and 
flow cytometry. Means±standard error from representative 
experiments are presented (n=3). As shown in FIG. 5, both 
primary T cells and lurkat cells displayed similar kinetics 
with appreciable lose of cell viability beginning as early as 8 
h post treatment and full toxicity effects requiring a longer 
treatment period of 24 h. 
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5. ZnO NP Induce ROS Production 
Several types of nanomaterials including quantum dots and 
metal oxide NP have been shown to induce the generation of 
excess reactive oxygen species (ROS) resulting in modifica-
tion and damage of cellular proteins, DNA, and lipids which 5 
can lead to cell death. To investigate oxidative stress produced 
10 
(p<0.000l) were observed between cultures not pretreated 
with NAC and both NAC pretreatments (5 mM and 10 mM) 
for each NP concentration tested. For example, with 10 mM 
NAC, nearly 100% viability was retained even at an NP 
concentration previously shown to reduce cell viability below 
10%. These results indicate that ROS generation plays a 
by ZnO NP as a mechanism of cellular toxicity, experiments causal role in NP-induced cytotoxicity. 
were performed using the cell permeable dye, DCFH -DA. In 7. ZnO NP Induce Apoptosis 
the presence of reactive oxygen species, including hydrogen Experiments were performed to determine whether ZnO 
peroxide and superoxide anion, DCFH-DA is oxidatively 10 NP induce apoptosis or necrosis in T cells. lurkat cells were 
modified into a highly fluorescent derivative that is readily treated with 0.3 mMNP for 20 hand apoptosis observed using 
detectable using flow cytometry. two different experimental approaches. In the first assay, cells 
According to FIG. 6, cellular production ofROS following were stained with a green fluorescent annexin V antibody 
ZnO NP exposure. ROS generation was evaluated in primary which reacts against externalized phosphatidylserine, a char-
T cells and monocytes and in the transformed Hut-78 T cell 15 acteristic of apoptotic cells, and the red fluorescent propidium 
line following 18-24 h of ZnO NP exposure using the oxida- iodide dye which stains both late-stage apoptotic and necrotic 
tion sensitive dye DCFH-DA and flow cytometry. A & C) cells displaying permeable membranes. As expected, viable 
Representative histograms depicting ROS production in pri- control cells show only very weak staining with annexin V 
mary T cells and monocytes. Assays were performed using antibody and no detectable staining with PI (FIG. 8). 
freshly obtained whole blood in which red blood cells were 20 According to FIG. 8, ZnO NP induce apoptosis in lurkat T 
removed following NH4Cllysis. T lymphocytes and mono- cells. Cells were left untreated, treated with 0.3 mM ZnO NP 
cytes were gated based on staining with f1uorescently labeled for 20 h, or treated with 100 nM okadaic acid for 20 h (positive 
CD3 and CD14 antibodies and the oxidation product of control) and stained with a green fluorescent annexin V anti-
DCFH-DA detected using the FLI detector. B) Histogram body to detect apoptotic membranes and the red fluorescent 
depicting ROS production in the transformed Hut-78 T cell 25 dye PI to detect permeable membranes using the Vybrant 
line. In each histogram, the light grey line depicts background apoptosis assay kit #2 (Molecular Probes). Cells were visu-
fluorescence in DCFH-DA loaded cells while the black line alized by confocal microscopy and representative images are 
depicts fluorescence in DCFH-DA loaded cells treated with shown. A-C) control cells not treated with NP; A) control 
ZnO NP for 18 h (A & C) or 24 h (B). To assess relative differential interference contrast (DICCimage, B) control DIC 
increases in ROS following NP treatment, a marker (M!) was 30 image with green and red fluorescence overlay, C) control 
set so that background fluorescent in control samples (DCFH - green and red fluorescence image. D-G) cells treated with NP; 
DA loaded/no NP) was between 1 and 3.5% and numbers in D) NP treated DIC image, E) NP treated DIC image with 
parentheses indicate the percentage of fluorescence positive green and red fluorescence overly, F) NP treated green and red 
cells. As shown in FIG. 6, a modest increase in DCF f1uores- fluorescence image. G) an additional green and red fluores-
cence was observed after 18 h of 5 mM ZnO NP exposure in 35 cence image ofNP treated cells oflower magnification. Con-
primary lymphocytes (-7.0 fold increase-12.5/1.78) and an versely, cells treated with ZnO NP stain positive with the 
even stronger induction observed in Hut-78 T leukemic cells apoptotic marker (eg. two out of the four cells in panel F and 
at 24 h (-14.0 fold increase). In addition, peripheral blood four out of five cells in panel G show green fluorescence 
monocytes produced robust levels (-25.1 fold increase) of only). Some dually stained were also observed as expected 
ROS following ZnO NP exposure consistent with the greater 40 for late-stage apoptotic cells with permeable membranes. To 
capacity of these cells for ROS generation. Increased ROS further verify NP-induced apoptosis, similar cell cultures 
production was detectable as early at 8 h of NP exposure were stained with the DNA dye, acridine orange, which is 
although greater levels were apparent at 18-24 h (data not used to detect apoptotic morphology characterized by nuclear 
shown). Because of the differing size and granularity proper- fragmentation, cellular shrinkage, and chromatin condensa-
ties of the cell types examined, different instrument voltage 45 tion. 
parameters were required which prevents direct comparisons According to FIG. 9, detection of apoptotic morphological 
of intrinsic levels of ROS between cell types. changes in lurkat cells treated with ZnO NP. Cells were left 
6. Role of ROS in NP-Induced Cytotoxicity untreated (A), or treated with 100 nM okadaic acid for 20 h as 
Experiments were performed to determine if the T cell a positive control for apoptosis (B), or treated with 0.3 mM 
death that results from NP exposure is dependent on the 50 ZnO NP for 20 h (C) and stained with acridine orange and 
generation of intracellular ROS. lurkat cells were exposed to visualized by fluorescent microscopy. Arrows indicate typical 
increasing concentrations of the antioxidant and ROS apoptotic cells characterized by a shrunken appearance and 
quencher, NAC (N-acetyl cysteine) prior to treatment with condensed or fragmented nuclei. As shown in FIG. 9, these 
NP for 24 h. morphological changes were observed in NP treated cultures 
According to FIG. 7, quenching of ROS protects against 55 and cells treated with the apoptosis inducer okadaic acid, but 
NP-mediated cytotoxicity. lurkat cells were pretreated with not in control samples. Collectively, these results indicate that 
5-10 mM N-acetyl cysteine for 60 min and then treated with ZnO NP induce apoptosis in lurkat T cells. 
0.3-0.5 mM ZnO NP.After 24 h, cell viability was determined Discussion 
using propidium iodide exclusion and flow cytometry. Data In this study we examined the toxicity profiles of human 
from a representative experiment performed in triplicate is 60 primary cells and transformed tumor cells to ZnO NP. 
presented with error bars depicting standard error. A two way Because cellular response is dynamic and the ultimate phe-
analysis of variance was performed followed by a model notype is affected by a myriad of competing or overlapping 
based means test to show significant differences in means of signals present in the microenvironment, studies were per-
cell viability (%) between treatments (asterisk denotes formed to determine how ZnO NP affect quiescent cells com-
p<O.OOOI). FIG. 7 shows that NAC has significant effects to 65 pared to rapidly dividing tumor cells and whether different 
prevent NP-induced cytotoxicity with rescue being observed activation stimuli result in different toxicity responses. Here 
at both NP concentrations tested. Significant differences we present novel findings demonstrating that cancerous T 
US 8,187,638 B2 
11 
cells are markedly more susceptible (-28-35 times) to ZnO 
NP mediated toxicity than their normal counterparts (FIG. 3). 
These findings may be of important clinical interest as one of 
the greatest challenges facing chemotherapy is the inability of 
anticancer drugs to effectively distinguish between normal 
and transformed tissue. Although many commonly used che-
motherapeutic drugs target rapidly dividing cells, many suffer 
from a relatively low therapeutic index, that is, the ratio of 
toxic dose to effective dose. This limitation frequently causes 
a broad range of toxicities leading to dose limiting toxicity 10 
and a concomitant reduction in antitumor efficacy. Impor-
tantly, the preferential toxicity of ZnO NP towards cancerous 
T cells is of substantial magnitude, especially in comparison 
to ex vivo indices reported for other commonly used chemo- 15 
therapeutic agents using similar cell viability assays. Thera-
peutic indices of ~ 1 0 have been reported for both doxorubi-
cin and carboplatin against a variety of tumors including 
acute myelogenous leukemia, non-Hodgkin's lymphoma, 
ovarian, and other solid tumors. Thus, the inherent differen- 20 
tial toxicity of ZnO NP against rapidly dividing cancer cells 
raises exciting opportunities for their potential use as antican-
cer agents, and the selectivity of these nanomaterials can be 
expected to be even further enhanced by design by linking 
tumor targeting ligands such as monoclonal antibodies, pep- 25 
tides, and small molecules to tumor-associated proteins, or by 
using NP for drug delivery. 
The preferential killing of rapidly dividing cancer cells 
relative to quiescent cells of the same lineage suggests that 
mechanisms of ZnO NP toxicity might be related to the pro- 30 
liferative potential of the cell. This hypothesis is further sup-
ported by studies comparing responses in healthy primary 
resting T cells to identical cultures in which cells were either 
activated thorough the T cell receptor signaling pathway or 
via both TCR and CD28 co stimulation pathways (FIG. 1). 35 
Signal transduction through the TCR pathway is recognized 
as an essential event required for resting T cells to enter the 
cell cycle and proliferate. A second signal provided by liga-
tion through the CD28 receptor protein augments TCR sig-
naling and enables maximal T cell activation and prolifera- 40 
tion. Thus, our findings revealing a spectrum of toxicity 
profiles that correlate with the activation status and prolifera-
tive capacity of the cell supports the hypothesis that ZnO NP 
preferentially target rapidly dividing cells. Quiescent T cells 
displayed the most resistance to ZnO NP while TCR stimu- 45 
lated cells had less resistance. Importantly, TCRlCD28 
costimulated T cells were the most sensitive to ZnO NP 
toxicity and a greater cell association with fluorescently 
labeled ZnO NP was observed in activated T cells compared 
12 
covalent attachment of antibodies specific to proteins 
expressed predominantly on activated T cells such as CD40L 
andOX40. 
A number of studies indicate that certain nanomaterials, 
including metal oxide NP, have the potential to exhibit spon-
taneous ROS production based on material composition and 
surface characteristics while other nanomaterials trigger ROS 
production only in the presence of select cell systems. Results 
from our flow cytometry experiments provide the first evi-
dence of ROS production in a biotic enviroument following 
ZnO NP exposure. These findings have important implica-
tions regarding mechanisms of cellular toxicity as elevated 
ROS production that exceeds the capacity of the cellular 
antioxidant defense system causes cells to enter a state of 
oxidative stress which results in damage of cellular compo-
nents such as lipids, proteins, and DNA. The oxidation of 
fatty acids then leads to the generation oflipid peroxides that 
initiate a chain reaction leading to disruption of plasma and 
organelle membranes and subsequent cell death. We observed 
a concentration and time dependent increase in ROS produc-
tion in primary T cells following ZnO NP exposure (FIG. 6), 
with even higher levels being observed in monocytes consis-
tent with the ability of these cells to generate large amounts of 
ROS during an immune response. Interestingly, immortalized 
T cells produced greater levels of ROS than primary T cells 
which may mechanistically underlie the greater susceptibility 
of cancerous T cells to NP-mediated toxicity. Indeed, studies 
using the ROS quencher, NAC, demonstrated the causal role 
ofROS generation in NP-mediated cytotoxicity (FIG. 7). 
As there is increasing evidence that elevated ROS acts as a 
critical signaling molecule in the induction of apoptosis 
induced by many different stimuli, studies were performed to 
determine ifNP induced cytotoxicity occurs via an apoptotic 
pathway. Results presented in FIGS. 8 and 9 provide strong 
evidence that ZnO NP induce apoptosis in cells ofT lympho-
cyte lineage. Collectively, these studies indicate that a pri-
mary mechanism of ZnO NP cytotoxicity may precede by 
inducing the generation of ROS which then underlies the 
induction of apoptosis, a process that may be prevented by 
antioxidants and ROS quenchers. These observations may 
provide the basis for the development of new rational strate-
gies to protect against NP toxicity or enhance the destruction 
of disease causing cell types such as cancer cells. 
Conclusion 
The key findings of this work support the view that ZnO NP 
induce toxicity in a cell-specific and proliferation dependent 
mauner with rapidly dividing cells being the most susceptible 
and quiescent cells being the least sensitive. The marked 
difference in cytotoxic response between cancer cells and 
to quiescent T cells (FIG. 1). These findings indicate that the 
selective elimination of activated T cells may be feasible, 
when desired, such as in the treatment of auto immunity. 
50 their normal counterparts, as well as differences between 
activated and resting T lymphocytes, suggests an exciting 
potential for ZnO NP as novel alternatives to cancer chemo-
therapy and radiation therapy as well as new approaches for In a number of autoimmune diseases including multiple 
sclerosis and psoriasis, self-reactive T cells are a pathogenic 
subset underlying disease processes and exist in a predomi- 55 
nately activated state as they are continually exposed to spe-
cific antigen present in normal body tissue. Because only a 
very small percentage of the total T cell repertoire are self-
reactive and pathogenic in autoimmunity, the ability of iden-
tical concentrations of ZnO NP to preferentially induce cyto- 60 
toxicity in self-reactive activated T cells while leaving the 
unactivated T cell repertoire largely intact and immunity 
uncompromised against future infections is an incredibly 
attractive approach which may ultimately become feasible. 
Based on data presented here, ZnO NP hold promise in this 65 
novel biomedical application, especially if their selectivity 
against self-reactive pathogenic cells can be improved by the 
treatment of autoimmunity. 
Although this invention has been described above with 
reference to particular means, materials and embodiments, it 
is to be understood that the invention is not limited to these 
disclosed particulars, but extends instead to all equivalents 
within the scope of the following claims. 
What we claim is: 
1. A method of killing cancer cells, the method comprising: 
providing a cancer cell in the presence of a healthy cell, 
wherein the cancer cell is from leukemia and/or lym-
phoma; 
contacting the cancer cell and the healthy cell with a ZnO 
nanoparticle, 
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wherein the ZnO nanoparticle has a preferential asso-
ciation with the cancer cell over the healthy cell, and 
wherein a targeting ligand is not associated with the ZnO 
nanoparticle; and 
killing the cancer cell. 
2. The method of claim 1, wherein the ZnO nanoparticle is 
at a concentration of about 0.1 mM to about 5 mM. 
3. The method of claim 1, wherein the preferential asso-
ciation of the ZnO nanoparticle with the cancer cell com-
prises intracellular uptake of the ZnO nanoparticle. 
4. The method of claim 1, wherein the ZnO nanoparticle 
kills the cancer cell via an apoptotic pathway. 
5. The method of claim 4, wherein the apoptotic pathway is 
induced by a reactive oxygen species produced because of the 
presence of the ZnO nanoparticle. 
6. The method of claim 1, wherein the ZnO nanoparticle 
induces the generation of reactive oxygen species within the 
cell. 
7. A method of preferentially inducing apoptosis in acti-
vated T-cells over resting T-cells, the method comprising: 
providing an activated T-cell in the presence of a resting 
T-cell; 
contacting the activated T-cell and the resting T-cell with a 
ZnO nanoparticle, 
10 
14 
12. A method of treating auto immune disease, the method 
comprising: 
providing an activated T-cell in the presence of a normal 
body tissue, 
wherein the activated T-cell has become activated due to 
multiple sclerosis or psoriasis; 
contacting the activated T-cell with a ZnO nanoparticle, 
wherein the ZnO nanoparticle has a preferential asso-
ciation with the activated T-cell over the normal body 
tissue; and 
generating a reactive oxygen species within the activated 
T-cell at a greater concentration than in the normal body 
tissue. 
13. The method of claim 12, wherein a targeting ligand is 
15 not associated with the ZnO nanoparticle. 
14. The method of claim 12, wherein the ZnO nanoparticle 
is at a concentration of about 0.1 mM to about 5 mM. 
15. The method of claim 12, wherein the preferential asso-
ciation of the ZnO nanoparticle with the activated T-cell com-
20 prises intracellular uptake of the ZnO nanoparticle. 
16. The method of claim 12, wherein the reactive oxygen 
species induce apoptosis. 
17. A method of treating cells exposed to a ZnO nanopar-
ticle, the method comprising: 
wherein the ZnO nanoparticle has a preferential asso- 25 
ciation with the activated T-cell; and 
providing a cell exposed to a ZnO nanoparticle; and 
contacting the cell with an antioxidant or a reactive oxygen 
species quencher. inducing apoptosis in the activated T-cell without exciting 
the ZnO nanoparticle with electromagnetic radiation. 
8. The method of claim 7, wherein a targeting ligand is not 
associated with the ZnO nanoparticle. 
9. The method of claim 7, wherein the ZnO nanoparticle is 
at a concentration of about 0.1 mM to about 5 mM. 
10. The method of claim 7, wherein the preferential asso-
ciation of the ZnO nanoparticle with the activated T-cell com-
prises intracellular uptake of the ZnO nanoparticle. 
11. The method of claim 7, wherein apoptosis is induced by 
a reactive oxygen species produced in the presence of the 
ZnO nanoparticle. 
30 
18. The method of claim 17, wherein a targeting ligand is 
not associated with the ZnO nanoparticle. 
19. The method of claim 17, wherein a targeting ligand is 
associated with the ZnO nanoparticle. 
20. The method of claim 17, wherein the ZnO nanoparticle 
is internalized into the cell. 
21. The method of claim 17, wherein the antioxidant or the 
35 active oxygen species quencher prevents the induction of 
apoptosis. 
* * * * * 
